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I. General Introduction 
Our efforts are being directed toward maintainence of actively secreting 
human pituitary growth hormone cells (somatotrophs) in vitro. The production 
of human growth hormone (hGH) by ~lis means would be of benefit for the treatment 
of certain human hypopituitary diseases such as dwarfism. Since the chemical 
nature of the factor(s) responsible for stimulating the release of hGH from the 
somatotroph is totally unknown, one of our primary approaches has (and will 
continue to be) testing of agents which may be expected to increase hGH release. 
This mid term report briefly summarizes our progress towards this goal. 
II. Tissue Procurement 
Shortly after initiation of this contract, we began setting up procedures 
for the procurement of human pituitary tissue. The following pathologists and 
neurosurgeons are collaborating on this project: 
Dr. Andrew Dekker, University of Pittsburgh, Pittsburgh, PA 
Dr. Olof PC3rson, Case Western Reserve, Cleveland, Ohio 
Dr. Robert Page, Hershey Medical Center, Hershey, PA 
Dr. Thomas Pretlow, University of Alabama, Birminghar,\, AL 
Dr. Bruce Northrup, Thomas J~fferson Medical School, Philadelphia, PA 
In all cases, these individuals min~e the tissue into ~ 1 mm 3 fragments 
and send them to Penn State in bottles containing 50 ml of sLerile medium 199 
containing 5\ horse serum and pCIl-strep (lOOlJ/ml). The se bottles, which are 
shipped at ambient tempcratur , usually arrjve in our laboratory ~ithin 24 hours 
a t er removal of the gland. Our samples from Pittsburgh usually arrive within 
18 hrs. Pertinent tissue information is provided in Table I. Note that in 4 
cases thus far, samples of tissue were obtained at surgery (biopsy) from patients 
with either breast cancer or pituital:Y tumors. 
TABLE I 
AUTOPSY SPECIHEN BIOPSY SPECIMEN 
Sample Number Age of Time After 
and Sex of Donor Source Donor Death Cause Cause 
1 0·1) ALA 70 4 hrs. He;trt Failure 
---
2 (F) CLE 55 ---- ---- Metastatic CA of Breast 
3 (F) CLE 75 ---- ---- Metastatic CA of Breast 
4 (F) HER 75 ----
---- Acromegalic 
5 (F) PHL 67 ---- ---- Pituitary Tumor 
6 (F) PIT 69 7 hrs. Metastatic Adenoc~rcinoma ---.-
7 (M) PIT 78 6 hrs. Emphysema, Pneumonia ----
8 (M) PIT 61 6 hrs. Congestive Heart Failure, 
GI Bleeding ----
9 (M) PIT 64 3 hrs. Malignant Neoplastic IV · 
Bronchus 
----
. 
10 (M) PIT 58 5 hrs. Metastatic Squamous Cell ----
11 (M) PIT 64 2 hrs. Adenocarcinoma of Cancer 
the stomach ----
12 0·1) PIT 6lt 6 hrs. Ruptured Abdominal Aneurism --.--
13 (M) PIT 58 6 hrs. Lung Cancer 
----
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II. A. Dissociation P~ocedure s 
The human pituitary is composed of pithelial cells supported by a signi
fi-
cant framework of fibrous connective tissue. It is tllerefore not surpris
ing 
that an enzymatic dissociation utilizing collagenase type r will yield m
ore 
cells than either collagenase type III (which presumably contains more lipase) 
or trypsin alone (Table II) . The chemicals us d in M thod I (s ee Table II) wer 
suggested to us by Dr. Gary r-tulde r of New York University Medical School 
(personal 
communication). Thus far, our; e xperi nce indicates it is the method of choice. 
Cell viability is usually 85\. Note tha t c 11 yield from autopsy mate ria
l can 
be quite comparable to that obtained from "fresh" material (cf sampl e 12 vs 4, 
Table II). Dr. Muld r informs me that his ce ll yields from autopsy rna t e rial are 
also ~ 2xl0 6 ce lls/gland. 
II. B. Light Microscopic Histology 
Herlants tetrachrome stain is especially us ful for the unequiv cal 
differentiation and identification of pituitary soma totro hs . Ye llow- s t a
ined 
somatotrophs prepared from "fresh" pi tuita r ies (b r ast canc r atients - Fig. la , 
b, c) or autopsy pituitary ti ss ue (Fig. I e , f) w r e c mmonly e ncount r ed . Th 
fact t.~at such ce lls assume a y 110w s t ain can be taken as posi tiv evid 
nc th.Jt 
they do indeed r e tain thei r intracellular stor .s of GH upon dis ociation.
 Exam 1 s 
of blue staining cells (basophils-TSH, FSH and LH Gells) arc also s nil . th s 
preparations. Using .3uch morphological crite ria, w conclude that ce lls 
from 
autopsy material are not diffe r e nt from f r esh material. Thi s in turn sugg
ests 
the feasibility of using autopsy mate rial for xp rim ntal work. 
The cells in Fig. ld we r e prepared from a n acr om galic pati nt und rgoing
 
hypophysectomy. Eve n though this patient's s rum GH levels w r e e l e va t 
d, the 
cells did not take on a ye l l ow stain in th ir cytoplasn~. In tea d, th y 
hav 
the typical appearance of tumorous cells. It is commonly b li v d that t
urnov r 
of GH is high in such cells, i. e ., one made , th hormon molecules ar r
a pidly 
r eleased. 
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TABLE It 
Autopsy(A) 
Dissociation C 11 or 
Sample fol thod Vi 1d Biopsy(B) 
2 3 1.7xlO
6 1 .5 PIT B 1 2.7xlO6 /0.5 PIT 
3 1 1. 5xlO 6 B 
4 1 3.bl06 B 
5 1 O.4xlO 6 n 
(, 1 NOT CO NTED ;\ 
7 
2 O.04xlO 10 . 5 PIT A 1 0 .3 dO 10 .5 PIT 
8 l NOT CO NTED A 
11 1 l.lx lO Ii A 
12 1 :" .5xlO6 ,\ 
13 1 O. JxlO A 
KEY 
~Iet hod 1: He dium 199 + 0.5% liSA + 0. ' • lIng Il:t se 1 
Hethod 2 : 
~I thad 3: 
NEH + 0.11 BSA + O.lZ trypRin (1: 250 ) 
lI a nkR + 0. 14 liSA + 0. 3. Ila gcnase III (o!loweJ 
by 19 + 0.1% B'A + O. 5. VlOKASE 
Fig. 1. Light microscopic photomicrographs of human pituitary cells prepared by enzymatic dissociation (Table II) and stained with Herlants tetrachrome stain. The cells with yellow staining cytoplasms are somatotrophs (5) whereas those with blue cytoplasms are basophils (B) - i.e., either T5H, F5H or LH producing cells . RBC's (R), chromophobes (probably prolactin cells) (C), and fibrous connecti ve tissue (F) are also idel' ··ified. 
a) Sample *3 - breast cancer pituitary 
b) Sample *2 - breast cancer pituitary 
c) Sample *2 - breast cancer pituitary 
d) Sample *4 - acromegalic pituitary 
e) Sample *7 - autopsy pituitary 
f) Sample *7 - autopsy pituitary 
(See Table! for tissue information). 
: .. ' , .. 
a b 
c d 
e f 
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~DU'''G 'AGlI&AN« NOr .fAkE~. III. Biogel C lumn Perfuslon 
Previous exp ri nco from our laboratory (Snyder and Hymer, End ., Sept. '71/ Snyder, Hymer and Wilfingcr, C 11 and Tissu 
al., ~., in press), as well s from those of others, cl arly shows that it 
is extremely difficult to maintain activ ly s creting s matotroph5 in convention 1 
monolayer for any significant period of time. This difficulty is pr bably du 
1) to lack of knowledge as to the ch mical natur of nativ growth hormon 
releasing factor and 2) to rapid overgrowth 'f e ithelial c lIs by fibro lasts. 
In 1974 a simple, yet pow~rful, techniqu w 1e cribcd by Lowry and his coworkers 
to stud~' til dynamics of horm n I." leas e from ituitary "11 il11!lObiliz d in 
columns of Biogel. This t chniqu has th mil j r adv.'ln age f rem ving pot"ntially harmful metabolites from the imm di a t vicinity f the 11s y n tant pc r-
fu - ion of th yst m. In th n xt s ec tion I wi ll briefly re 1 t ur 
with rat pituitary cells in Oi '1 so tha tlF ' read r an a f lin f r h 
III. A. R ts 
In our usual e 'p"riment, xl f i t uita ry "11s ill." l'a k~'d in ..: ml s yrin 
with 0.15 gm • of r'sw 11 n Oi "1 p- lumn h i';Jht :: l). ml). Th f 
th column is constru t"d with a "sandwich" f ny x ( ~I ) and milll r<:' U) 
filt rs to pr v nt 11s fr m s ping tll c lumn. Buff r is rum cd 
of th column (flow rat • 0.5 ml / min) by means f 
an 
column eluant i 11 "ct"d in t.ub s with a fra i B h h' buf "r 
v 55 1 and lumn ar' imm''' r s in l\ 37° \.U\ t 'I." b. h. Lin s nil 'cti n wi h he 
:nain inl t line by 3-w y valv s p _rmit on t a ur ly "ruls " t h c 11 wi 'h 
a variety of s ct" tago u S .:it ny d sir d int rv 1. 
Shown in Figur 2 (to ) i9 " a" I" Gil iOll • 3 
- minu , 
ft r tartin th exp rim'n r 1 tiv h rtnOn" i 
w 
~ 
:::> 
z 
-~ 
" 0 
w 
.-
w 
a: 
u 
w 
CJ) 
w 
z 
0 
~ 
a: 
0 
I 
. ~ 
~ 
~ 
0 
a: 
(!) 
0' 
C 
200 
30 
8 
Fig. 2 
~ 
E 
Q 
a. 
~ 
« 
(..) 
~ 
E 
- . 
a. 
:E 
« 
(..) 
~ 
E 
~ 
~ 
10mM cAMP 
120 150 
9 
achieved. The response of the cells to graded doses of dibutyryl cyclic AMP 
(0.01-10.0 roM) is also shown in Fig. 2 (bottom). A 2-minute pulse with this 
cyclic nucleotide will stimulate GH release in dose-related fashion at concen-
trations above 0.1 mH. This is a highly repeatable response in the rat system. 
In other experL~nts (not shown) the response can be potentiated witb theo-
~hy11ine, a prosphodiesterase inhibitor. In these experiments the column 
buffer was Medium 199 containing 0.1\ BSA. 
The versatility of the Biogel column technique is exemplified by the data 
shewn in Fig. 3. In this experiment 3 columns, each containing 5xl06 cells, 
were run concurrently. The respons ' repeated 2' pulses of 1 mM cAMP is 
clearly evident in Fig. 3A. Inclu5 . ,of somatostatin (SIF) in the column 
buffer dampens basal release and p •. :events cAi-tP stimulated release (Fig. 3B). 
Perfusion of w~~ cells with SIF immediately afte r cAMP will, for a time, dampen 
the secretory r~sponse. Eventually, however, large "breakthrough" peaks are 
routinely en~ountered (Fig. 3C). 
Our experiences with prostaglandins (E series, El and E2) are typified by 
the data in Fi~. 4. A sharp rise (~ 420 ng to ~ 1650 ng) in GH r e lease occurs 
within 1 minute after pUlsing with 10- 9 M PGE2' A less dramatic response was 
obtained with 10- 8 M PGE2 (Fig. 4, top). We have also noted an in~eresting 
difference between the responsiveness of lightly granulate-j ('l','pe I) vs heavily 
granulated (Type II) somatotrophs to 5xlO- IO M PGEl (Fig. 4, bottom). The two 
types of somatotrophs were separated on the basis of density differences , i.e., 
density gradient c entrifugation through heavy BSA . 
. 
In summary, these data collected on rat pituitary somatotrophs have prompted 
l1S to begin comparable experiments with human pituitary tissue. 
III. B. Humans 
1. hGH RIA. To do these experiments it was first nec ssary to obtain a 
hGH RIA kit and establish the assay in our laboratory. 
W 
t-
=> 
Z 
-~ 
....... 
Cl 
w 
t-
W 
a::: 
u 
w 
CJ) 50 
w 
z 
0 
~ 
a:: 
0 
:r: 
:r: 
~ 
~ 300 
0 
a:: 
(!) 
0' 200 c 
100 
A 
B 
C 
10 
Fig . 3 
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The assay employs the immunochemical hGH (Batch #HS2243E) and guinea pig 
antiserum to hGH provided by NIAMDD and a sheep anti-guinea pig gamma globulin 
serum. Factors affecting th~ iodination of hGH with 1131 and assay variables 
such as antibody and 1251 concentrations have been critically examined (Figs. 
SA and 5b). The lower limit of sensitivity of the assay is 0.025 ng, allowing 
detection of as' little as 0.25 ng of hGH/ml of .sample. 
2. "Pieces". While we were gai ning experience with the enzymatic dissociation 
of human pituitary tissue (Table II) we carried out 2 separate experiments tn which 
minced pituitary pieces (1 mm~) were placed on top of the biogel column. In both 
of these experiments 2 columns running concurrently were used, each receiving the 
eq\Aivalent (i n wet weight) of half of t.he available tissue (essentially 1/2 of 
a gland. Pituitary glands from autopsy material were used in both experiments 
(cross reference Fig. 6 with Table I for detailed information). In both 
experiments, one column buffer was medium 199 + 0.1\ BSA ~ secretagogue (CRMP 
or PGEl) while the other column buffer was identical except it also containe d 
10-9 M hydrocortisone (He). This was included because we had shown in earlier 
studies that this steroid promoted synthesis, but not release, of GH in rat 
somatotrophs. 
From the results in Fig. 6 the following conclusions are drawn: 
a) Over the 5 1/2 hour period, the quantity of GH ranged 300-800 ng/ml 
(note ordinate scale cha:1ge betv/een Fig. 6 top and bottom) . 
b) After ~, initial period of rapid decline in GH release (also seen in 
t.'1e rat system, e.g., Fig. 2, 3, 4), "basal" levels r emained fairly constant 
after 'V 1 hr . 
c) Addition of hydrocortisone to the medium had no effect on Gil r e lease 
over this relatively short time period. (Longe r time periods are currently 
being tested). 
d) cA!·:O (30' pulses) did not stinmlnte GH r elease as it do es in the rat. 
In fact, at the high dose it tended to s uppress release. 
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e) There tended to be a "rebound recovery" in GH r e lease afte r the pulse 
of 10 mM cAMP. 
f) PGEl had little effect on GH r e l ase unde r these particular e xperimental 
conditions. 
3. Ce lls Our preliminary e xp"rienc s with the GH 
s e cretory performance of dispcrs'd cells pr'~~ r~d f~om auto~sy mate ri a l (sec 
Table II for methodology) in the Biegel column syst'm is dep i cted in Figs. 7 and 
B. Note that the initial high Gil It:vcls in the e arly fraction s fall precipitously 
to a relative ly constant basal rate'\, 1 hr. a ft e r the s tart of the experiment. 
This fall can probably not be attributed to the di s$ociati n proc--dure since it 
also occurr d wh e n "pi 'ces" were used (cf Fig. 6 ). It '01 uld pp'ar that the l e vel 
of basal s ' c r tio n is r L' 1 t ed t o the am unt of tis s ue in the column. Thus , it wa s 
'V 25 ng/ml "'h e n 1.1x10 6 c lIs we r ... ' us ed (Fig. 7 ); 'V SO n I ml wh n 2. xl 0 6 CL'lls 
were us d (Fig . 8) and ." 600 ng/ m1 whe n '\, 112 o f a pi tuit;. t'y g l a nd w.:\s USL'd 
(Fig. 6). 
It i s obvio us fr m Fig. 7 a nd Fj g . 8 th.'lt the c mbilMtion of ll)- ~ ,., PGEI 
an 10- C) H hydrocor iso lle do's not augtn"nt reI 'ase of h ,II o ver thL' time pl riads 
(up t o (. hrs .) of th", se cxpe rim nts . Also not -- t ha t in 1us ion of erum in 
th " column buff'r does n t .aff ect the basi r L'lcasc I'att'rn. At t Ill' time of 
writing th is r ~ r· ware conducting a seri0s f 'xp~rim nts to examine t he 
efft!cts of PGE I a nd 1\ n GlI rl!l eas~ fr m somatotr I'hs maint i ncd in Bioge l 
for much longe r p e riods 24 - 36 hrs .) . 
4. Cell s - Bi t's y Hate ri,,1. TIl"' dynamics f Gi l ["('1 ,'\se fr m di s l'c r s d cells 
prepared from fresh p ituitary ti ~su (i. e ., s urgi ca l sp'cim,' ns ) ;lr.~ s hown in 
Figs. " 10 a nd 11. In two cas's tI l<' bas al l('v'ls ar s url'risillC) ly l ow ('V 
We have no t'xplanati n f o r this I'0s ult at th PI' Sl'nt lime. 
ng/ ml) . 
The b sa l r 1 as' 10vels from ( II approxill\dt" ly (' lu i vd1 nt number of acro -
mcga lic cells (3. 0xl0 6 C0 1lS ) was consid0I'ably h i h'r ('\. l )( ng/ml, Fig. 11), ,'l 
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SAMPLE 4: CELLS (3.8 x 106 ) - BIOPSY 
BUFFER: a MEM + 5% CALF SERUM ± PGE 1 + HC t 
.-
BUFFER 
64 128 192 256 320 384 448 
. T IME (MINUTES) 
result which probably reflects their hlgh secretion rates in vivo. The data 
generated in Fig. 11 are derived from an aliquot of the same cell sample 
depicted in Fig. ld. 
As with the autopsy-cell data (section 111-3, above), it seems clear 
that nelther cAMP, HC, PGEI nor serum have appreciabl e effects on the quantity 
of hGH released from cells prepared from biopsy tissue. 
IV. Isoelectric Focusing of Rat Pituitary Cells 
One of the goals of our contract is the purification of Ii ving hwnan 
!'omatotrophs utilizing s everal t echniques, including de nsity gradient isoe lcct.ric 
focusing. As a start on this subproject, we lhlve carri ci out several experime nt s 
utilizing rat pituitary c e lls as the mode l syst~. 
A modified version of the i50elcctric focusing t echnique d e s c ribe d by Boltz 
e t . a1. (l, 2 i has b "n us d in attem~t5 to sl'I'arate rat a nt rior pituitary cells. 
The apparatus use d in thes~ e xp rimc nts i s s h \"n in Figure 1 2 (1). Til '1' trod .. , 
v ss e is were fill d wi th an a nod' soluti n f 1 H 1131'0 .. ;lnd ath de so lution 
of I H NaOH. A " ce iling" solution of 35 ml o f 1 i, ht ci..' ns ity sol uti o n was i.nj(' t "d 
into the column through th ~ CJnidi~nt inl't. Thi s Wu S follow:X! by .1 <i<.ms ity .lradicnt 
forme d using a gradi nt-mal< r to mix a li ght (S . 7 S llc ro' " l. l)1. -:l Iu l)S(') a nd a 
he vy (10\ ficoll , B.O\ s u rose , 1.0\ glll-os L') den s ity !:o l\ltion. E.1 h o f t ill'S" 
gra di ent solutions con ta ine d 1. 0 \ (w/ v) umpho lin ' 5 obt .lilh'd f rom LKH and l . (W l mllmlml 
Fas t Green F F d)' uSl'd .1S a III mark r (3) . The d .. ' ns ity gradipnt W.I ~ f 11 w,' 
by a "floor" solution of 30\ S1; ros to fini s h fi llin thl.' o lumn. \~.1t,'r was 
continuously circulatt.'d around t he col umn t,1 enro l c lumll l .. 'ml'erature. Th e 
e l ec trodes within the '1 c trode vess Is wen' IlllL'c ted t a LKD ( _ll' ) I' "'('r 
supply. Th e pH gradient was forme d by pas s ing A m.l ximum urr nt of _ mJ\mps 
through the column, volta e varied from 400 volts t o ll)lh' v,l lts At compl i, Il. 
Aft e r x}'(\ s ure t o thi s c u rrent f o r 1 2 -1, ll0u rs , lll, ' dy\.' h .ld fo used in t o a 
seri s of na rro w bands in t il ' ac r ylamidc pl\lq of t h' illl 11.' v,' ss'1 .1 1l i i ll tlw 
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Glassware for density gradient isoelectric focusing of cells. 
Shaded blocks are fittings made of machined teflon. The 
height of the cooling finger is adjustable while the column 
is filled, so sample can be admiFted at any desired pH after 
the pH craJient is formed. Tile sidea rms of the electrode 
vessels are filled with lSI polyacrylamide gel plugs mold ed 
in FJsition. The ammonium persulfate was ionophoresed from ~ 
these plugs prior to g adient formation. y~G~ rl 
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ceiling :;olution whe r the pH was 3.0. This indic,'lt d that ttll~ ."\mpho1 ines 
h4d completed fomati n f the pH qradi.:!nt, and that the (" lumn was r ad)" f r 
insertion of the cells for is lcctric fusing. 
A 1. 2-ml sample f the pH-d nsit} gradient was r"mov~d from th" column 
with 11 tuberculin syringe atta h d to the salnl-'le in1 t . The 1'1-1 of that I'I0rti n 
of the gradient at th~ ntry port was det'lminuJ f1 ' m this s."\mp10. !f an ther 
}':'H '<'4S desired for e ll loading, the gradient s."\mp10 .... s reinserted, th0 entry 
port moved to an ther position ""ithin tlH: c0lumn, and the pr caurf' rep'at d. 
Antt't'i r pituitari '5 ..... '1' n~rnoved fI m :--10 Fisher ~~ f 'I'!\.'lh' r.lts 
(105-108 da~ s ldl. They wer,' diss0 i:ltcd f r :. h ours with trYl'sin (l: ~ r: 1, 
Difcol susp oded in Eagl,'s minim\Ull L' ~~sl'nti.11 m'dium ",taln':n 1 . H. 11$1\ (~,. 
l'taining l.l\ 1'S1\ , ."\n~i ,"\.~ untL'd in .l IIL'n\1cyt .. ' l1l<'t Cl". An .11i'1\~~t ,,'nt..1ininQ 
-1 xl0 6 cells \".lS rL' l1lC'\',d fn: m tJ", .. el1u1.11 ' \' n'!'\1r.lti 'Jll .\lld \, .l :~hL'd .1 ~,' lhi 
tl \(\t is, it ... ·.15 IwId in .\ tl\b<'r~'ul in S YI i 1\\.1" .1l till' ~ .l l1l,' t ,' :7.!' l' 1'.1 t un' ,15 t Ill' .. '('lumn 
h.u'vt.'st in 
25 
cell counts were made for every other f raction. Cellular peaks were then 
id\.;ntified, and all r emaining fractions within th ese peaks were counted. 
Cytospin slides were then made of the control fraction and the pooled ce l _ ~lar 
peak fractions. These w<;!re stained 'with Herlant's tetrachrome stain for identifi-
cation of cell types. 
Quantitative data relating to cell ~ecove i~ in fOUl isoelectric focusing 
experiments are given in Table III. Recove ry of cells fron ' th e electrc-phoresis 
column was'" 50\, regardless of the temperature, time, or pll range of the 
gradient employed in the experiment. Especially noteworthy is the ~ recovery 
of cells after sitting in the insertion buffer at the same temperature for the 
same time as used in the electrophoresis run. It is clear that at insertion 
pH's which are acid (5.2-5.8), only 5 0 ~ of the cells are r e covered. Howeve r, 
at a higher insertion pH (7.2), c e ll r e cove ry was consid.~ rably e nhanced in the 
control cells (82\), eve n though r e cove ry from th e e l e ctropho r es i s co lumn run in 
this same experiment was only 4 2 ~. Ta k e n t og, til er , t h ese r esul ts c l ea rly show 
that some pituitary c e lls cannot \"i thsta nd a c idi c pll' s. Approxima te ly SO\ of 
those that were inserted at pH 7.2 in th e e l c tro pho r es i s c olumn did not survi Vl~ , 
presumably b ecause th e y f ocused at th acidi c I'll. We are c urre ntly e va ' ,: 'lting 
stained sample s to sec if th e ce ll loss .1 t a c id pI! i s p r cf(' r c ntial to 1 (o r mo r (' ) 
cell types. 
Distribution p rofil e s of th e c e lls \yithin th ' p H g radi e nts afte r isoe l ec tric 
focusing are s hown in Fig. 13. Th e se pro fil s s how on e l 'o pul a t io n of c e lls 
consiste ntly focu s ing a t p ll tV ~\. 25 . Oth e r s arc u s u.1lly r cov·.'rcd at pll '" 5,(" 
and some are ofte n found at p H 4. 9 . Th ese ~' .:l t ~. ' rn s seem t o -' r e a sona b l y i ndc -
p e nde nt of the e xpe rime nta l c ondi tions of t mpe r a ture ( 4 0 \' s 1 r. O) a nd time ( e,() , 
vs 180 ') . 
A detail ed histological e va luat ion of th ' ce lls i n the di f f e r e n t g r a di e nt 
fraction s i s b e ing do ne a t th e time of wri t ing t h i s re ~'()I't . 
I! 
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Table III 
Ampholine II Cells 
I Exp. II Temp. Time pH range % Loaded (OC) (min) (x 10 6) 
NP-22 4 60 4-6 1 10.7 
t iP- 23 1 5 180 4-6 1 10.1 
NP-24 15 60 4-6 0.5 4.4 
5-8 O.S 
NP-26 15 70 5-e 1 I 8.3 
--- ---
+Percentage of cells recovered from electrophoresis column. 
++ Perc~ntage of cells recovered from electrophoresis column buffer. 
but were maintai~ed in the electrophoresis buffer at the insertion 
terms of temperature and time) to those being electrophoresed. 
% Cells 
% Cells Recovered 
Recover ed from ++ Insertion 
+ Buffer pH 
51 41 5.2 
52 50 5.5 
43 48 5.85 
42 82 7.2 
These cells were not electrophoresed, 
pH under conditions identical (i.e., in 
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V. a. SUlI'II\ary 
Tlte 60U(}(4.liI'ig 6.ttu:emenU aJld eoncttL6.toIt6 6unmaJUze OWL pIlogILM6 OVVl the 
p~d 5/1/78 - 11/1/78. 
1. We have 6U: up 6ucee666ut tiMue pltocWlemettt pltoeedWle.6 w.uJt 6.ive eoUaboJr.a.U119 
neWl06Wlgeon6/pa,tJto!og-iAu a..t U,uVeJt6U!j h06pit;a,U aCllo66 tlte eowWr.lj. 
2. We have devei.oped me..tJwdologiu to diA60citLte human p-<--tuaMIj U.66Ue (ob.tLU.l1ed 
eilheJt at tULtop61j OIL 6 uJlgVllj I .into 6.ingie ee.u. 6tL6Petl~.i0I't6. U~ ,iIl9 Med.i.um 199 
eonta-illing 0.5% BSA /lJtd 0.3% coteagelllt6e I, we can Obtiu:.11 '\, 2:d0 6 6{lIgie. ee.U6 
wlu.c./t call be d.i.66tVle.Ilt.<.ate.d a t the light mtClt06 COptC te.ve.l'. .ill to VaM17U6 
p.{.tu,Ua)t1j edt tljpM. No cU66C1leltce6 .vt tire moltpllotogiea.i quaL<.ty 06 ceil6 
be-tween autop61j a.lld b.top~y 6pec.i.me.1't6 llilve been 6eVt tlttL6 6M. 
3. The vatA.dU:1j 06 tlte. Bioge..t c.e.U. c.otW7111 PCJl6u6.ioll 6Y6ter.: 60't tdudy.tllg tire 
dynam.i.~ 06 GH IlcteJt6e lut6 been dcvc1.opc.d alld docunlellted IL6i.1t9 a 'tat paLl,dallY 
c.e.U 6lj6 tem. The 6eCllwgogu1!,6 cAMP and PGE 1 Me bo tit e66ective. .til augmenting 
GH ltei.e.a6e (F.ig6. 2-41. 
4. A 1rA91:f.y 6 ett6it,(ve JutcUo,wJ71U1Wa6 My 60Jt IrGH 11it6 beeJl e6 tabU~/re.d .{II lVl 
.ia. b 0 lta.to Illj • 
5. On tlle b.'t.~,{,~ 06 data. p'lC ellted .vI F.ig. 6, d appCiL'W tllat H'e. can !Jucc.M~6uU.y 
tlbe. 1 17171 3 p.c>c.e6 06 IlU1IItUl pLtIU.taJt.y W.W"- t r mOIl.i.tc,'l Itciclt~e (16 IzGH. 
App.'ledabte q(~aIlC.Ltie.6 (300-800 Itg l mtl 06 IrC-1( Me ,'letc(ueci WId 'I. tlre.H. C,LltC.W71-
6 tanc.M. 
6. cAA(P dOi:, ~ I ! t 6t(111UCtt itCH ·'I.rf.ca6 (tit 6act i..t ma l) ac.tuaCfI/ 'supp~c.s~ Itcfra&e). 
Pllo~ta9e.ailtti.1l6 aJld ltyd·wc(1'1. t( .~ lie have IW a66ec.t 011 IzGH llt'eCIl~e wtd 'I. tize 
c.ondUi.oIl6 06 Oil/[ e.xpe.lt.{lI1eltt6. 
7. Re~utt6 ~(mi.ett,'t tt' tllO~e dc.sc.'t-i.bcd {II 14 5 alld 14 6 above Iravc hcc lI (lbta.{IIe.d wizen 
6.tllgl'.e c.eLt 6lt-.spellJ tOIL'sj Mt/r 't titllH ).tiece.!I, Cl'tC. ({..s ed <.lIthe. 8.i.oge.t. 
8. No 6wlc.tuJllaf. Olt loolz.plIo(og ic.IL d.i66''I.cI1C~6 o'twc.ell cct'C..s doivcd. 6'tOlTI autu~y 
V6. b.i.op~y ma,tCJt..<aC :zavc be.ell d' tec.ted till!.!. 6CL't. 
9. ReAu,t.t6 6.1wIn ..se.V 'LIlt p'l.eC{,millalz.!1 exl-' liml' II{.:'\ dl'a i'i ll !l (ll {.t/( tlr r i~ (JCC)C.t.HC. 
60c.u4.ing 06 ltat pttu,(tCl'l.!( "e.H~ 'sWI9~.'d t/tat til'tre c.rN ", ~.lUell.tioll~ nOc.U4.tllg 
at pH' 6 06 4.9. 5.25 alld 5.6 Mr 6e.r.v'r~ (1~e by rlt,{~ tcd(1l i.qlle. 
V. b. Futurc Experimcnt.,l Plans 
In the next 6 IOOnths of the p~' : ~ . ct we .will continuc our sC.lrch for agents 
which we have reason to be li'vc stand a r asolldL>le C h,:l/)~8 of a ugm 'nting r lease 
of hGH from human pituitary tissup in the Bi oge l s ystem. Many o f the experiments 
will be done witll "pi e ces" and cffective stimulatory agents will be subsequently 
retested on dispcrse d cclls. I f ee l our tis s ue procuremc nt program is getting 
I ~ 
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into "full swing" now, and more samples can be reasonably expected. In this 
specific regard, I had originally told Drs. Dekker et al., not to provide any 
material older than 6 hrs. post-mortem. I now feel this requirement was 
probably too conservative and we have relaxed our requirements to 18 hrs post-
mortem. Finally, we recently obtained autoclavable lcc glass microchromatography 
colmruns to use for the Biogel experiments. With this new set-up, we should be 
able to carry out perfusion ~xperiments for a good deal longer, thereby enabling 
testing for long term effects of the presumed secretagogues. 
Among the new agents we propose to t est are a) cholera enterotoxin, b) Tmi, 
c) ascites fluid from a rat mammary tumor, b) plasma from acromegalic patients, 
e) intact rat hypothalami, f) rat hypothalamic extracts and g) purified growth 
hormone releasing factor (GRF). The use of rat hypothalamic mate rial is suggested 
since this tissue contains GRF which is not spe ci es specific; i.e., it should act 
on human somatotrophs. In addition, we are nego t iating with Drs. Nair and Wilbur 
of the University of South Carolir.a Hedical School for some of t he ir puri fi ed 
(14 aa) GRF prepara t i on. 
With regard to the e lectrophoresis a pp roach t o pituitary c e ll s eparation, 
we propo~e to evaluate the following modifications: a) co lumn ~ompos ition 
(~. e ., ampholine Goncentration, pH range , ficoll conce ntra tion, buffer sys t ems), 
b) ins ertion pH' ~ (to examine the possibility ~1at p rote ins are be ing stripped 
s equentially from th P. membrane surface during e lectro~hore s i s ), and c} the use 
of density gradi ent r. l ect1.0pho r esis for lituitary ce ll s eparation. 
30 
1. R. C. Boltz Jr., P . Todd, R. H. Hammerstedt, W. C. Hymer, C. J. Thompson, 
and J. Docherty. Cell Separation Methods (1977) 1 ~ 3 . 
2. R. C. Boltz, Jr., P. Todd, R. A. Gaines, R. P. Milito, J. J. Docherty, 
C. J. ThJmpson, M. F. D. Notter, L. S. Richardson, and R. Mortell. J. 
Histochem. cytochen. 24:16 (1976). 
3. A. Conway-Jacobs and L. M. Lewin. Anal. Biochem. il:394 (1971). 
4. W. C. Hymer, W. H. Evans, J. Krbicer, A. Mastr0, J. Davis and E. Griswold. 
Endocrinology 92: 275 (1973). 
Addendum to 
Mid-Term Report 
for 
'NA~A Contract NAS 9-15566 
Purification and Cultivation of Human 
Pituitary GrO\~th Hormone Secreting Cells 
by 
W. C. Hymer 
Professor of Biophysics 
Department of Biochemistry & Biophysics 
The Pennsylvania State University 
University Park, PA 16802 
November 1, 1978 
• 
L t, J t 1 1 ' I l ~ [ _L:l t I~.~ 
A2 
I. General Int~oduction 
The need for an adequate supply of human pi tui tary growth hormone (hGH) 
for the treatment of children with growth hornone deficiency (GHD) is well 
recognized. Ms. Alice Maurer, a NASA employee, ~as recently written an 
informative and interesting report relating to <.=HD. For the reader's information, 
and for purpose~ of this Addendum, the following excerpts are directly quoted 
from her report (references omitted) ... 
The cardinal manifestation of GH deficiency (GHD) in childhood is 
growth failure. When GHD is congenital, birth weight and length 
are usually normal but growth retardation becomes apparent within the 
first or second year of life, the height of these children almos t 
invariably being three standard deviations below the mean for their 
age. If untreated, severe growth hormone deficiency leads to true 
pituitary dwarfism, with the individual retaining the stature of 
a tiny child even in adulthood. Even the less extreme forms of GHD 
frequently result in some degree 0f psychological damage to the 
child who is consistently mistaken for one several years younger 
than his peers. 
Estimates of the prevalence of GHD in chi.ldren vary widely, from a 
high of 1 in 60 to 1 in 30,000. Recently, the Scottish Survey of 
Short Stature reported an incidence of 1 in 4018 for severe growth 
hOrbl0ne deficiency in children in three Scottish cities. Whatever 
the actual prevalence cf this condition, most workers agree that 
hundreds of thousands of children exist who could benefit from GH 
therapy, and that growth hormone deficiency is probably a severely 
wlderdiagnosed affliction. 
Ideally, GH replacement therapy should be institnt..ed in infancy, as 
response then is far better than when treatment is de layed until 
dwarfism is well established. At any rate, growth hormone must be 
given before the time when the epiphyseal plates, those actively 
proliferating cartilage layers of the long bones , become clcsed. 
Closure of the epiphyses, a process associated with impending puberty, 
u~ ually s t arts at about a~e 10 and is completed by approximately 
18-21 years in males . Cha~acteristically, the growth o f a GHD child 
on GH therapy manifests a "catch-up" curve, being maximal in the first 
three months of treatment and gradually ~alling off after that, 
although growth gains continue through9ut puberty if GH administration 
is maintained . Some workers suggest that intermittent GH therapy, 
with several months "off" the hormone being alternated with "on" 
periods, prevents the progressive decline in growth velocity which 
characterizes continuous therapy. However, most recent studies in 
chis field indicate that continuous treatment is of greater value in 
achieving the maximum height gain. 
Selecting the proper GH dosage for the treatment of GHD is dete rmined 
not only by therapeutic considerations, but also by the stringent 
limitations which the scarcity of this substance imposes. Presently, 
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GH for th~rapeutic use is derived soley from human cadaver pituitary glands, 80,000 of which are collected annually by the National Pituitary Agency (NPA), a division of the National Institutes of Health. The NPA coordinates the collection ann dispersment of human pituitaries for research, diaqnostic standardization, and commercial production in the United States. Cal Biochem. Company, this country's only GH supplier, supplements their pituitary supply with material 
collected in South America. Cal Bioche~. does not sell the product to pharmacies or wholesale distributors, but only to the physician 
who has submitted a formal request along with clinical and labora-tory evidence proving growth hormone deficiency in the prospective patient. In addition, GHD patients who are serving as research 
subjects in an approved project may obtain the hormone free of charge directly from the NPA. 
Following the empir i cally derived recommendations of Raben and Escamilla, the maj01"ity of GHD patients receive GH dose:; of 2 IU three times a 
week, or 312 IU per year. Frasier has suggested that a lower dose, 
although perhaps not therapeutically optimal, would more efficiently 
utilize the limited GH supplies. Based upon measurements of plasma GH levels, he recommends a tri-weekly dose of 0.06 IU per kilogram 
of body weight. Ma~on, however, points out that de terminations of plasma GH levels are a less desirable index of Gil therapeutics than 
are the levels of somatomedin, and suggests that the future monitoring of GH therapy will be nehanced by the development of sensitive somato-
medin receptor assays. Nevertheless, current therapeutic practice generally "requires the administration of 312 IU of GH per year, to be 
continued until a satisfactory height is achieved or the epiphyses 
close. At a cost from Cal Biochem. of $300 for 40 IU, this amounts to an annual expense of some $2240. 
These informative data on GHD clearly establish the need and desirability 
for alternative methods of therapy. One approach, of course, is via r e com-
binant DNA technicology. Several laboratories a re attempting to get GH genes, 
which have been introduced into the E. coli genome, translated. If successful, 
sufficient quantities of GH would then be available to meet th~rapeutic demand. 
A second approach could be the implantation of a living h uman pituitary cells 
into t he brains of GilD patients. The rationale fo r t h is approach will become 
apparent in the following sections of this adde ndum. 
A4 
II. Growth of Un 
Cell Implant3 
aring Intrav ntric14r Pi tuitary 
About two years a90 we discovered that lq)lantation of ncut ly disper!1od 
pituitary cells int the lateral bl'ain vcntricl s of hypox rats r sulted in 
partial restoration of growth for periods of 1-3 months. This obs rv tion 
prompted a study of the Hect, th r 'sult of which will app ar in the Oecemb r 
issue of Proc. So . EXp. 8i 1. Mod. A pr dnt is "'n 1 sed with tills addendum. 
The follO'lOing stat ments sl.UMIarize this study: 
a. growth (\ weight ain) f niNls b arinl) lxl06 c lls waR simil. r, 
during th first 3 we k post -implantation pe d d, to sham- hypophys 
tomiz d littermat s. 
b. growth was pl'Oporti nal t numb r fells il1\-' 1, nt~d. 
c. 1 n'1 b IW l cnl1 h ,,'as signi fi antIy '1l" a ter i n th~ ('xp rill\'.' ntal group. 
d. body II\position al\.:l1ysis sh 'II 'ct thi\t "Ilimals in th,' ~'xl'erill\'nt"l 
gr UI' put on protuin whilf' th ~ t in th~ nt 1'01 qroul' it i n t. 
)' un'l e r l"t' il'ients grew b~~ tt r th..,n olct r 1\,"'8/ ells !l'o m I'ituitarit's 
of Ider don r s <1 VE b~ttt r l"t:lS pOI\Sl' th.\ll ~quivc\l u l\t t'l1 numh rs 
from '1lMlds f )'O\Ul\)t:'r d 1\ rs. 
f. pur if i ct onlal I ' I'h ~ 9.\v", " I' sit i ve ,' {'SI ns t:! . 
q. ast r ation did 1\ t :\ffe~t tlw r~s~'-'IlS", a n'sult whi h SII'-19,'sts th t 
anab li~ st,~r ids (t~st steron,"') ai'" I'[\)t'><\bly not involv,-.\. 
h. inl1lul)01 gic-<\lly l'~t,~ 't. bl Gil was Iwt"d ill tho l'rains f l't' il'i"llt~l 
I 1\\Jllth ~ st- iml'l i'mt(\t iOIl. lIow,'vur, .11 W.\S !lo t d~ t t.,bl.' in th 
l'\!riI'hl'ra1 !H,'[' um f t.h,su .I\i",,'\ls . 
In d f w I'il t xl't'l'im"lIts we n0t,'ct that illll'ldllt.\ti"l\ f I'itlllt.lry ~ ,'Il s 
from 1 st rain of n,ts int0 lin x d no n: f."\ ~nl »tl',\l1I r .. ·sulttld ill qn")wth 
f r only a Sh0I"t ",hile. We t ntativt'ly intt'l"!'l',·ttd this ttl-l'n'vi. l,'d resp,. lI s ,' 
to i 11111\\11 ~ 11 s i 1\ til,' l'S F • 
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If the pituitary cell implantation approach described in the preprint 
is to stand any chance of being therapeutically useful for the treatment of 
GHD patients, the problem of tissue rejection must obviously be addressed. 
Our approach to this problem is described in the next section. 
III. Growth of Hypophysectomized (HYPOX) Rats Bearing Intracranial Capsules 
Containing Pituitary Cells 
A. Diafiber Hollow Fibers: Characteristics 
Several years ago Amicon Corporation (Lexington, Mass.) marketed a product 
which consisted of a very thin anisotropic Oiaflo membrane and a thicker spongy 
layer of the same polymer wi th increasingly larger openings. These hollow 
fibers are made of a polyvinyl chloride-acrylic copolymer (l<r'1-50) with an internal 
diameter of 1000 ~m and controlled pore sizes with a nominal molecular weight 
cut off at 50 ,000. Examples of their structure are shown in Fig. lA and B 
(taken from the Amicon catalogue ). 
Use of these fibers for the production of artifical pancreas units is 
becoming trore widespread in the r esearch laboratory. Bas icall y, the concept 
is one of attaching pancreatic islet cells to the surface of an enc apsulate d 
fiber which, in turn, is subsequent ly implanted in a diabt?tic a nimal in su~h 
a way that blood is flowinq through the lumen , of th~ fib e r. Ins ulin, by virtue 
of its molecular size, pe rmeates the pore of the hollow fiber and e nters the 
blood stream. However , the animal's ilntibody producing c 11s or IgG molecules 
(150,000 ,.,.01) arc too large to get at the pancreatic tissue . The usefulness of 
th e idea of an implant.lble artificial ndocr-ine pancre as unit to r e store 
normoglyc mia in diabet ic rats has been expcri m ntally ve rified (e .g., Tze et 
al., Nature, 264, 466, 1976). 
B. Capsule Implantation 
We reasoned that inserti"n of pituitary cells into the lumen of the XM-50 
hollow fiber, follow d by implantation of the fiber into the brain of the 
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DIAFIBER HOLLo\.J FIBER ELECTRON 
MICROGRAPH (200X). Ultrafiltration 
"skin" faces internal channel. 
Cylindrical substructure opens 
progressively outward. 
DIAFLO MEMBRANE ELECTRON MICROGRAPH 
(SOOX). Ultrafiltration "skin" is 
invisibly thin at the very top. Open-
celled substructure is highly perm-
eable to filtrate . 
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hypox rat, might promote growth in the recipient when pituitary tissue of 
different species were used (heterografts). Shown in Fig. 2A are fibers 
imp lanted into the rat brain coronally (top) or parasagittally (bottom). Even 
though the capsule takes up a large area of the brain, it has no obvious 
visible effect on tlle behavior or physical i\ppear~nce of the animal. nlese 
preparations were done by Dr. R. Page of the Hershey Hedical ('e nter. None of 
the fibers get into the hypothalamus. They ofte n approach a ve ntri cula r ,;urface. 
Shown in Fig. 28 and 2C is the appearance of th e capsules removed 1 and 7 days 
post-implantation, respectively. Note that the pituitary cells are singl e 
after 1 day, but after 7 days have aggregated and assume some of the charactcr-
istics of an intact pituitary gland. Also note that cells invade the capsule 
to the point of the limiting membrane. Som havtC' tllt~ appearance o f polymorpho-
nuclear lymphocytes. 
C. Growth o f !\nimals Bearing Intran-dnial Cap~ ul s 
Shown in F ' . J is the growth of ilYPOX 6 ra ts o ver a 55 - day }'e riod. Some 
receive d empty ibers (control s ), some rec'iv'd il l'~ul 's containing ~.Rxl () b 
I-
pituita ry ce lls from th e same s tr.-.in (~I 'rag\It'-D~.dl'Y) ,lnd otlH'rs rl.'~t'i\'ed cal's ul e ~ 
e nc los e d r-\..~) we know thdt tlw \\' ~'ight gai n i n contn.---ls i s att rib\lt:l b~e to fdt. \ containing small pil'cC's vf r .'\t pituitary tis~;\le. Fr m I'rC'vi u s wl~rk (s ee 
It is el e-a r tl\at ~'i (,c l's / ct~ lls of r a t pitultary ti :; '; Ul' art' ,ll'able of lhJml.'ntin~! 
animal grcwth. Pres umably r GlI (r·n" 2 .. , 0(1(\ ) will l',l ~S tltrouCJh tlH' "(), POl) MH 1 rl'S 
and act (eithe r within the br.:lin its<--lf or i ll the g. 'lwl"ill :: irc uLlt iC'n) t 
promotc g row th via tilt' SL)OlatC'r.lccii n nlt-'chanism. Sl\o"' n ill Fi\} .. J ,1.l"l' t h e- rcsult · 
Tht" C'xl'crimt.'ntal resu l ts depi c t d ill Fi qs . :' atld , .H· ,) int,' n'gtin ill lIght 
o f t.h t! co nsid rati ns d i s usst' d i n t hl' bl'gi llllin f tit i ~ fHkklldum. Th us , 
pituitary ce ll s from a ctiffcre llt ~ tl'"il\ f r,lt s (f- J -l ·I), s ll l' l'I ' , C'r Inundlls aI',' 
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all capable of eliciting a positive and significant ;rowth response. Such da~ 
argue for the usefulness of this approach in the treatment of GHD patients . 
D. Scanni~g Electron Microscopy of Capsules 
Preliminary SEM's of several capsules removed from rats 30-50 days post-
implantation are reproduced in Fig. 7A-D. Thg empty capsule (Fig. 7A) reveals 
brain tissue on the outer surface, sometimes settling into the crypts of the 
fiber (Fig. 7B). The nature of these cells is unknown at the present time, but 
we suspect that they are l~nphocytes. The appearance of rat pituitary cells 
(Fig. 7C) or cow pituitary cells (Fig. 70) in the lumen reveal a rough surface 
which is characteristic of functional pituitary cells. 
IV. Summary 
The need for an adequate supply of hGH and/or new experimental approaches 
to the therapy of GHD has been described in both the mid- term progress report 
as well as the Addendum t o this report. During the first year of our NASA 
contract one of our major goals has bEen, and will continue to be, the search 
for agents which may be expected to augment release of hGH from the human , 
pituitary somatotroph maintained in vitro. When coupled with our attempts at 
isolating s omatotrophs by electrophoretic techniques, the magni~ude of t he 
project is such that a second year of support will certainly be requested. 
(This was so indicated on pg. 12 of the original proposal). In the original 
proposal we indicated that part of the effort in the second year would be related 
to selection of ... "histocompatible somatotrophs for potential implantation by 
. using a labeled anticody technique to modify the electrokinetic properties of 
cells bear.ing histocompatibility antigens." From the preliminary data presented 
in Fig. 6 it appears that we may have already discovered a way to overcome the 
problem of tissue rejection for this particular application (i.e., implantation). 
It is important to indicate tha t ~ he data generated in Figs. 2-7 of the 
Addendum were done so with no federal support. Money for the purchase of hypox 
/1.15 
: 
rats (4 substantial f : gure) w s provided to us by Dr . Robert Pag , a neurosurgeon 
at the Hershey f.ledical Center of The P nn ~ta University . Dr . Page is an 
expert on mammalian hyp ttalamo- hypophysial blood vas ulature. lie has been 
involvdd ill the "xperimental design f the implantation stu ies and is obviously 
& scientific collaborator on them . Due to circum ~anc~s bey tld hi control, 
Dr . Page rec ntly indicat d to m that he will n I ngt'r b" abl t r rovid 
financial su port for this PI j ct . 
This 3ddendum to our mid-t rm r port w s included t e tablish that our 
in vivo im lantation approa h is 1 arly comratiilc with II ~ vitro hGil 
studies curr ntly support d by our AS;:" t. ur curr~nt thinking is to 
rcqu st, in the r e ncwn 1 i llication t Nl\SJ\ n 'xt Nay, SUI'I rt for ,\ scri s f 
cxperim'nts inv lvillg : 
1. ontinU'd in vitro aplro.l c hes f r th' ui t ivati n t'f activ 1y ee l: tin 
human l'ituitdry omat tr)l= lIs (as dct~'rmil1t'd by sp~' ifi h.II r;tdi inununo-
ssay) ; 
,-
c ntinu~'d .'It'etl" rh reti' ,11't'l"oaclll's t th,' S"P,lt-'lti. 11 of rat/ hunnn 
s mat tro l lis; and 
3. utili;:a i on f he intr.k'r.l lli.ll fll'su1l' iml'1. 11 t..l tl 011 t" _hniqup to study 
the bil'l - ':liea! activity f hUm.lll ri tui to'\ ry ~l.'m .. ' U't r"l'ils ~ vi v\ . 
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Running Titl Pituitary Ce ll Transplants 
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Surgical remo'~il o! the adenohypophysis in young animals results in retarded 
growth as well as decline in peripheral endocrine organ function. Attempts at 
demonstrating recovery of growth by means of heterotopic hypophysial transplants 
have met with only limited success (1-5). For example, Halasz and associates 
reported that transplantation of the whole pituitary gland into the hypophysiotropic 
area of the brain resulted in part ial restoration of growth (3). Growth restoration 
of a smaller magnitude was observed after transplantation of pituitary glands to 
s~ch remote sites as the renal capsule (2) or anterior chamber of the eye (1), 
as well as intramuscular (5) or subcutaneous (4) placements. Gittes and Kastin 
(5) observed a log dose relationship between growth and number of intramuscular 
glands and by extrapolation concluded that 750 glands would be required for 
restoration to normal growth. Meites and Kragt (4), on the other hand, reported 
partial restoration of growth (46\) in young (37-day-old.) hypophysectomized 
(hypox) ~ rats bearing a single subcutaneous pituitary for 30 days. 
The ease with which pituitary glands can be enzymatically dispersed to yield 
suspensions of single viable cells is no\i widely appreciated. In addition to 
~1eir usefulness for in vit~0 studies, these single cell suspensions have also 
been irr~lanted i nto the kidney capsule or hypophysiotropic area of hypox rats 
(6,7). On the basis of morpho ogical criteria it was suggested that such trans-
planted cells retained functionality in vivo. 
There is increasing evidence that cerebrospinal fluid (CSF) contains 
(hypothalamic) neurohormones (8) which may participate in the regulation of 
pituitary function (9). In the present study, the ventricular system of the 
brain of hypox rats was therefore chosen as the implantation site for dispersed 
pituitary cells and th~ restor~ tion of body growth was used as an index of function-
ali ty of the i',lplan ted cell::; . 
MATERIALS AND METHODS 
In the usual experiment, hypox Sprague Dawley male rats weighing 80-100 g 
(~ 30 days old) were purchased from Charles River Breeding Laboratories, Inc., 
[CD Strain (OUtbred Albino), Wilmington, MA) and permitted one week of post-
operative recovery. In some cases, sham-hypox littermates were also used. 
Twenty-gauge hypodermic needles, filed to an uribevelled end 3.25 mm in length 
and filled with silastic, were stereotaxically implanted into the left ventricle 
and anchored with acrylic cement according to the procedures of Severs et al. (10). 
Animals were maintained one additional week prior to cell implantation. During 
this period, animals showing increases in body weight of > 5\ over initial post-
operative levels, suggestive of incomplete hypophysectomy, were discarded from the 
experiment. Anterior pituitaries from donor males of the same strain (CD, 250-
400 g, > 70 days) were dispersed in trypsin (11), counted, and resuspended in 
"lOOck CSF", consisting of 16 mg dextrose, 176 mg NaHC03, 15 mg KCl, 14.0 mg CaC12 
(anhydrous), 8.1 mg NaH2PO~oH20, 23.5 mg MgCllo6H20, 13 mg urea, 91 mg NaCl in 
~f'._ ml dO\'~le distilled water. Each animal received a single injec t ion of 10-20 ~l 
either "mock CSF" (control) or l-3xlO b cells prep.:>.::ed in CSF vehicle (experimental), 
delivered via the needle of a microliter syringe through the silastic plug of the 
indwelling cannula. The quantity of cells delivered was equivalent to approximately 
1/4-3/4 of a whole pituitary gland. Three to 6 animals were used per group. The 
an'mals were maintained with 5% glucose in their drinking water a nd allowed lab 
chow ad libitum, under a 12-h light (0600 to 1800) cycle, for periods up to 3 
months. They were weighed 3 times per week. 
In one experimental series, body composition analysis was done accordi ng to 
the procedure of Hartsook and He rshberger (12). m~~ e xpe rimental prot oco l 
involved analysis of 12 hypox rats (80-120 g) 2 weeks post-sur gery (group A) 
and 12 hypox littermates which had received either "CSF" or 2xlO b c e lls 2 weeks 
post-surgery fol l owed by a 30-day gr owth peri od (group B). Regression analysis 
B~ 
of the body composition ddta from group A gave the following equations for 
prediction of initial body compositions of animals in group 8: Dry ma tter = 
0.34 (BW) - 4.77 [r~ w .95), Lipid = 0.1 (BW) = 4.07 (r 2 = .79); Ash = .04 (BW) -
.31 [r2 - .90)J Protein = 0.2 (BW) - .71 (r~ .94). This protocol permitted 
evaluation of changes in body composition over the growth period. 
Growth hormone (GH) was measured with a double antibody radioUrumunoassay 
procedure (sensitivity, 3 ng/ml) with materials provided by the NIIIJ>100 (Rat 
Pituitary Program). Protein content of brain homogenates was estimated by the 
Lowry procedure (13). 
Growth curves were analyzed by the variance ratio test on double reciprocal 
plots of log weight gain vs. log time. This transformation yielded lin ar graphs 
and randomly scattered residual variance plots. Compara tive growth responses 
at 30 days post implantation, as well as other data (bone l engths, body compo-
sition and hormone l evels) were analyzed by ANOVA or, when appropriate, Student's 
t-test. 
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RESULTS 
Growth response. During the fir.~~ 3-week post-implantation period, growth of 
hypox animals bearing lxl0 6 cells, expressed as \ weight gain, was similar to that 
of sh~hypophysectomized littermates (Fig. 1). After this time growth tended to 
plateau (see Fig. 1, EXp. *1 and #2, lxl06 cells). The growth response was 
related to the number of cells implanted. At no time did total growth exceed that 
of the animal with an intact pituitary; however, animals receiving more cells 
tended to plateau later. A single injection of 3xl06 cells resulted in a doubling 
of the animals' body weight over a period of 3 months (Fig. 1, insert). Implanta-
tion of lxl06 cells into the ventricles of non-hypophysectanized rats resulted in 
slightly, but significantly (p<.05) depressed growth curves. 
There was an increase in tibial and femoral bone lengths measured either radio-
graphically or on bones dissected from the rat£ at autopsy (see Fig. 2). In both 
cases bone lengths were significantly (p<.05} longer in the experimental group. 
There was a positive correlation between the two methods of measurement. Actual 
tibial, femoral, and pelvic lengths were 3l.~.29, 26.~.33, 29.6~.24 rom respectively 
for controls and 33.8~.88, 28.9~.24, 33.3~.44 mm for experimentals (lxIO° cells) . 
Correlations with x-rays were r = .77 (tibia), r = .84 (fibula), r . 97 (pelvis). 
Body composition. In a separate experiment, 30 day old hypox 6 rats receiving 
2xl0 6 cells intraventricularily showed weigh t gains over 30 days of 22.~0.5 g (SEM) 
(~ 34\ increase in body weight) vs. 7.5+1.4 g (~ 11% increase in body weight) for 
those receiving "CSF". The increase in the experimental group represented 14.1~3.5 9 
dry matteI' of which 5.0~1.5 9 were protein, 8.5+1.9 9 were lipid, and 1. ~0.5 9 were 
ash. The increase in the control group represented 2.8~0.5 9 dry matter of which 
0.1+0.3 9 were protein, 2. 6~0. 7 g were lipid and O. 4~0.1 9 were ash. These results 
clearly show that significant (p<.05) increases in both protein and fat account for 
the we i ght gain in the experimental animals. 
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Age and sex. Younger recipients showed a better growth response than the 
older ones (Fig. 3, top). Pituitary cells from older donor animals gave better 
responses than cells from young animals (Fig . 3, middle). Cells from male donors 
of different ages gave consistently inferior responses ',,:hen implanted into young 
hypox females (Fig. 3, middle vs bottom). This result is consistent with the 
observatiun that male rats grow larger than females. Cells from') 70-day-old 
female donors were as effective as their male counterparts when transplanted into 
hypox males (data not shown). 
Somatotroph implantation. Intrav~ntricular implantation of 630,000 somato-
trophs purified to 90% by the method of Snyder et al. (14) resulted in a weight 
gain at 3 days of 17.4~3.6\ vs -1.5~4.3% for those injected with vehicle (p<.05). 
Castration. Four groups (n=5, each group) of hypox recipients, two of which 
were castrated at the time of pituitary removal, received either 2xl0 6 pituitary 
cells or vehicle. Growth (\ wt. gain) 30 days post-implantation was as follow~: 
a) castrated animals with cells 45.8+10.8\; b) castratEd animals with vehicle 
5.3+1.5\; c) non-castrated animals with cells 69.1+15.0\ and d) non-castrated 
animals with vehicle 9.1+2.7\. Growth of animals at 30 days in both experimental 
groups was significantly greatel- than in controls (p<.05), but not significantly 
different betwe en experimental gr."lups. 
Brain and blood growth hormone (GH). The levels of GH in homogenates of 
brains prepared from animals receiving either lxl0 6 pituitary cells or vehicle is 
given in Table I. The data reveal detectable hormone in the brains of the e xperi-
mental gcoup 30 days post-implantation , but at 1/4 the leve l detected 12 days 
post-implantation. 
GH levels in the sera of each of the animals in Table I were, in every case, 
undetectable. possible reason(s) for this result are curre~ tly under study. 
Cell placement and viability. In four separate experiments designed to 
assess requirements of cell placement and viability in re:ation to the ~rowth 
'1 
I I, 
I 
,. 
I f 
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response, the following data were collecte~ (\ ~t. gain in 30-day-old hypox males 
one month post-implantation): a) lxl0 6 cells - intraperitoneally, l3~4\; 
b) lxl0 6 cells-anterior chamber of the eye, 7.8~2.4'; c} heat-killed (56 0 C, 
30 min) cells-intraventricularily, 4.7~; and d) a 100,000 x 9 particle fractj.on 
(prepared from lxl0 6 cells) 5.4~0.3\. None of these responses were significantly 
different from vehicle-injected controls, but all were significantly lower (p<.Ol) 
than the response obtained by implanting lxlO' cells intraventricularily 
(40.6~4.0', mean of the four experiments). 
HistOlogy. Serial sections of the entire brains of several experimental 
animals rev~aled epithelial cells in the 3rd ventricle, lateral ventricles, and 
subarach id space. Since such cells were nut found in the sections of the brains 
of a control animal, it is tentatively concluded that the pituitary cells spread 
throughout the entire ventricular system. 
I 
1 
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DISCUSSION 
The key findl.ng in this study i!; that implantatio~1 of pi tui tary cells into 
the ventricular system of hypophysectomized rats results in animal growth. This 
growth is reflected both in increased bone length as well as deposition of total 
body protein. Our data show that intact cells placed in the ventricles are 
required to obtain this respons~ since neither cells placed in the anterior 
chamber of the eye or peritoneal c3vity nor heat killed c e lls or p ituitary 
organelles gave a positive growth response. 
The gro.ith response can probably be attributed to somatotrophs in the 
pituitary celJ suspensions for the following reasons: first, implantation of 
purified somatotrophs gave a positive response; second, the response was obtained 
in a castrated animal in which influences of anabolic steroids were not present; 
and third, GH was detected in the brains of rats 30 days post-implantation of 
cells, but not in vehicle-injected controls (Table Il . 
The results show that the CSF of the hypox rat provides a s uitable functional 
r.ri.lieu for maintai:lence of somatGtrophs for at l east 3 weeks post - implantation . 
An abstract describing some of these findings was ublished in Fee. Proc. , 
36 , 363, !977. The ~tudies were supported by NSF grant B~~ 71-015 8. 
l\IIIIlIliti.-,""""",~-u._;J...1 ..... ;~tJL....;o..""""....lj , .-L...! ~--L-l_..J...--' 
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SUMMARY 
Implantat.ion of acutely r.ispersf;d adenohypophysial cells int.o '....he lateral 
ventricles of hypophysect-::nuized rats resulted in p~r ~..J. rll growth restoration 
for periods of O!1e to three months. \'ieisht gain by experimental anirnuls was 
consistently 20\ to 60\ greater than a~ng hypophyse~tomi~~d control rats; the 
response was related to t~e number of ~ells implanted. The weigh gain reflected 
increa:;es of both prote i . C:"l ,j :at i n body con"F.Jsitioll. A "iglll.fiCnot inr.rease 
in long bone lengths was also observed am,')ng rats b ,:>l'.:'irg intr,'\v€Tltricular cells. 
Intraven~iculaL impla"ltation of either heat-k illed anterior pitu~tary cell~ or 
subcellular organelles, ')r implantation of pituitary cells in the peritoneal 
cavity or antericr charr.,bt.= r of the eye, dio. not promote signifl.can+-, growth in 
hypophys e ctomized recipients . The results suggest that transplanted growth 
honncne-secreting cel1E are provided with a suitable func 'tional milieu by the 
cerebrospinal fluid of the hYj;:0physectomized rat. 
BIl' 
REFERENCES 
1. Goldberg, R. C. and Knobil, E., Endocrinology 61, 742 (lS~/). 
2. Hertz, R" Endocrinology 65, Y;!6 (1959). 
3 . Halasz, B. I Pu~p, L., Uhal!.'ik, S. and Tirna, L., Acta Physio!. (Acad. Sci. 
H~lg.) 23, 287 (1963). 
4. Meitas, J. and Kragt, C. L., Endocrinology 75, 565 (1964). ./ 
5 . Gittes; R. F. and Kastin, A. J., Endocrinology 78,1023 (19661. 
6. B01fTie, E. pP . f Anat. Rec. 187, 540 ~1977). J 
7. Yoshimura, F. I Earumiya, K., Ishikawa, H. and Ohtsuka, Y., Endo
crino!. Japn. 
16, 531 (l969). 
8. Joseph, S. A., Sorre,-,tino, S. and Sundberg, D. K., in "Brain-En
docrine 
Interaction. The ventricular System in Neuroendocrine Processe~." 
U<. ~1. Kni,]ge, D. E. Scott, F. Kobayashi, and S. I shii, eds .) p. 306 
Karger, Basel (1975). 
9 . Kni.gge, K. M., Scott, D. E" Kobayashi, F. and Ish ii, S., in "B
r-ain-Endocrine 
Interaction. The Ventricular Sys tern in Neuro~ndocrine P.r(),~l:sses." p. 
? 
(Karger, Basel), (1975). 
10. Severs, W. B., Summy-Lonq, J., T<lylor, J . S., and Conner, J. D
., J. Pharmacol. 
Exp. Ther., 174, 27 (19 70). 
11. Hymer, W. C. , Kraice r, J., Benco!:;rilc , :, . A. "lnd Haskill, J. S., 
Proc. Soc. 
EXp. BioI. Med. 141, 966 (1972). 
12. Hartsook, E. W. and Hershberger, T., Pro~,. ?oc. Exp. ~jo1. Med. 1
13, 973 (1963). 
13. Lowry, 0., Rosebrough. H. , Farro' J.\. a ;111 Randall, J., J. BioI. 
Chern. 193, 
265 (1951). 
14. Snyder , G., Hymer, W. C. ani,:, ~' nyder , J., Endocrinology 101, 788
 (1977). 
811 
Table 1. Growth hormone levels (ng GH/mg protein) in 
br"in hcmogenates prepared from hypox rats previously 
implanted with lxlO' pituitary cells (experimentals) 
or CSF vehicle (controls). 
Days Post-Implantation 
Treatment . ., 1.. 2LJ 30 
. 1 a Exper:Lnl nta s 53 . 4+9 .0 b 16 . 1+4 . 1 13 . 6+2.3 
Controls 3. 2+3. 2 Oc IHO 
a30-day-old hypox 0 rats r eceived lxl0 6 pituitary ci~l !': from 70-day-old 0 rats. 
b Standard error of mean. 
cOne animal; all other groups had 3-4 animals. 
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FIGURE LEGENOO 
Fig. 1. Exp. II, percent increase in body weight of ~ 30 day male hypox r a ts 
receiving a 10 lJl intraventricular injection of either "mock" cerebral 
spinal fluid (CSF control) or lxlQ' single pituitary cells from 70-day-
old donors (bottom 2 lines) or sham hypophysectomized littermates + IxIO' 
pituitary cells (top 2 lines). Each line corresponds to the weight gain 
of 4 animals1 error bars and shading represent ~ SEM. Effect of implan-
tation of lx, 2x (Exp. *2) or 3x10' cells (Exp. 113) on weight gain is 
shown in the inserts. 
Fig. 2. Radiographs and bones (tibia-lower, femur-upper) from 2 hypox animals 
30 days aft~r intraventricular implantation of either 2x10' cells 
(left) or "mock" CSF vehicle (right). Scale bar equals 1 cm. 
Fig. 3. Effect of age of recipient at hypophysectomy (top), and age of donor 
pituitary cells in 6 recipients (middl~) or ~ r ecipients (bottom) on 
weight gain. Statistical analysis! top pane l: one animal in the 30 
day experimental group grew 3x more than the other 3. Analysis of 
variar.ce (J\NOVA) on these data ex..: ludi ng this single animal resulted 
in significant (p<.05) elevations in the f:'xperimental groups in all cases. 
Middle panel: by J\NOVA 50 and 70 -uay-old donor. cells caused s i gnifi-
cant (p<.05) growth. Bottom pane l: growth, although aplarently 
elevated, was not statistically s ignificant . 
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